Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0K4RK
|
||||
Former ID |
DNCL003319
|
||||
Drug Name |
Blinatumomab
|
||||
Synonyms |
AMG 103
|
||||
Drug Type |
Monoclonal antibody
|
||||
Indication | Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10:C91.0] | Approved | [1], [2] | ||
Company |
Amgen
|
||||
CAS Number |
CAS 853426-35-4
|
||||
Target and Pathway | |||||
Target(s) | B-lymphocyte antigen CD19 | Target Info | Modulator | [3] | |
T-cell surface glycoprotein CD3 | Target Info | Modulator | [3] | ||
KEGG Pathway | PI3K-Akt signaling pathway | ||||
Hematopoietic cell lineage | |||||
B cell receptor signaling pathway | |||||
Epstein-Barr virus infection | |||||
Primary immunodeficiency | |||||
NetPath Pathway | IL-7 Signaling Pathway | ||||
PANTHER Pathway | B cell activation | ||||
Pathway Interaction Database | BCR signaling pathway | ||||
Reactome | PIP3 activates AKT signaling | ||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
Constitutive Signaling by Aberrant PI3K in Cancer | |||||
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||||
WikiPathways | Human Complement System | ||||
Signaling by the B Cell Receptor (BCR) | |||||
PIP3 activates AKT signaling | |||||
B Cell Receptor Signaling Pathway | |||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | ||||
REF 2 | ClinicalTrials.gov (NCT02393859) Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL | ||||
REF 3 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.